Dechra Pharmaceuticals Plc

  • Market Cap: N/A
  • Industry: Pharmaceuticals: Major
  • ISIN: GB0009633180
GBP
38.66
0.02 (0.05%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

2.04 M

Shareholding (Dec 2021)

FII

50.17%

Held by 544 FIIs

DII

0

Held by 5 DIIs

Promoter

0.46%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

GBP 4,404 Million ()

stock-summary
P/E

59.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

32.32%

stock-summary
Debt Equity

0.55

stock-summary
Return on Equity

9.81%

stock-summary
Price to Book

5.83

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.9%
0%
1.9%
6 Months
4.54%
0%
4.54%
1 Year
31.14%
0%
31.14%
2 Years
-7.95%
0%
-7.95%
3 Years
8.29%
0%
8.29%
4 Years
26.01%
0%
26.01%
5 Years
59.23%
0%
59.23%

Dechra Pharmaceuticals Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
13.34%
EBIT Growth (5y)
18.74%
EBIT to Interest (avg)
7.09
Debt to EBITDA (avg)
1.36
Net Debt to Equity (avg)
0.55
Sales to Capital Employed (avg)
0.61
Tax Ratio
23.30%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.02%
ROE (avg)
8.88%
Valuation key factors
Factor
Value
P/E Ratio
59
Industry P/E
Price to Book Value
5.83
EV to EBIT
51.07
EV to EBITDA
26.19
EV to Capital Employed
4.11
EV to Sales
6.33
PEG Ratio
NA
Dividend Yield
32.32%
ROCE (Latest)
8.05%
ROE (Latest)
9.81%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2021stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 544 Foreign Institutions (50.17%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Dechra Pharmaceuticals Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2023 is 11.69% vs 12.14% in Jun 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2023 is -147.94% vs 4.86% in Jun 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'23",
        "Jun'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "761.50",
          "val2": "681.80",
          "chgp": "11.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "183.80",
          "val2": "189.90",
          "chgp": "-3.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "23.10",
          "val2": "8.80",
          "chgp": "162.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-105.40",
          "val2": "-19.50",
          "chgp": "-440.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.90",
          "val2": "58.20",
          "chgp": "-147.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "123.60%",
          "val2": "148.90%",
          "chgp": "-2.53%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Jun'23stock-summary
Jun'23
Jun'22
Change(%)
Net Sales
761.50
681.80
11.69%
Operating Profit (PBDIT) excl Other Income
183.80
189.90
-3.21%
Interest
23.10
8.80
162.50%
Exceptional Items
-105.40
-19.50
-440.51%
Consolidate Net Profit
-27.90
58.20
-147.94%
Operating Profit Margin (Excl OI)
123.60%
148.90%
-2.53%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2023 is 11.69% vs 12.14% in Jun 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2023 is -147.94% vs 4.86% in Jun 2022

stock-summaryCompany CV
About Dechra Pharmaceuticals Plc stock-summary
stock-summary
Dechra Pharmaceuticals Plc
Pharmaceuticals: Major
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine, Food producing Animal Products and Nutrition. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal, Equine and Food Producing Animal Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos, Zycortal and Vetoryl.
Company Coordinates stock-summary
Company Details
Lostock Gralam , NORTHWICH None : CW9 7UA
stock-summary
Tel: 44 1606 814730
stock-summary
Registrar Details